The Asia Pacific is currently ranked third in terms of revenue from the depression drugs and devices market, where the expected growth rate of the antidepressants drugs, devices, and therapies market is 3.32% CAGR during the forecasting years of 2019-2027.
China, India, Japan, South Korea, Australia and the remaining countries constituting the Rest of Asia Pacific segment are considered for the market study. The high cost of psychotherapy restraining people to take services, which is acting as a major hindering factor for market growth. Drug makers witness a downfall of almost xx% of their revenue as soon as they lose patent protection. With the patent expiration, other companies get the rights to produce low-cost generics.
The companies are eminently functioning in the APAC antidepressants drugs, devices, and therapies market are Pfizer, GlaxoSmithKline, Abbot Laboratories, Brainsway, Neuronetics, Mayo Clinic, F. Hoffmann-La Roche Ltd., H. Lundbeck AS, Eli Lilly and Company, Allergan PLC and Boehringer Ingelheim GmbH.